This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
MDPV: Difference between revisions
>David Hedlund remove "'''Bath Salts''', '''Monkey Dust''', among many others" from the lead -- see https://en.wikipedia.org/wiki/Bath_salts_(drug) ("Bath salts (also called psychoactive bath salts, PABS[1][2] and, in the United Kingdom, monkey dust)[3] are a group of recreational designer drugs.") |
>David Hedlund restored '''Monkey Dust''' |
||
| Line 3: | Line 3: | ||
{{SubstanceBox/MDPV}} | {{SubstanceBox/MDPV}} | ||
'''3,4-Methylenedioxypyrovalerone''' (also known as '''MDPV''') is a novel lesser-known [[psychoactive class::stimulant]] substance of the [[substituted cathinone|cathinone]] and [[substituted pyrrolidine|pyrrolidine]] classes. It is known to be one of the most powerful and potent stimulants. MDPV is thought to act primarily as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI). | '''3,4-Methylenedioxypyrovalerone''' (also known as '''MDPV''', and '''Monkey Dust'''<ref>{{cite news |title=Monkey dust "epidemic" causing drug users to experience violent hallucinations |url=https://www.newsweek.com/what-monkey-dust-bath-salt-mpvd-drug-causing-epidemic-violent-hallucinations-1068295 |access-date=17 August 2018 |work=Newsweek |date=10 August 2018 |language=en}}</ref>) is a novel lesser-known [[psychoactive class::stimulant]] substance of the [[substituted cathinone|cathinone]] and [[substituted pyrrolidine|pyrrolidine]] classes. It is known to be one of the most powerful and potent stimulants. MDPV is thought to act primarily as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI). | ||
MDPV was first developed in the 1960s by a team at Boehringer Ingelheim.<ref name="KoppePatent">{{Citation | vauthors=((Koppe, H.)), ((Ludwig, G.)), ((Zeile, K.)) | title=1-(3’,4’-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1) | url=https://patents.google.com/patent/US3478050/en}}</ref> It was claimed to have potential to be an alternative for racemic amphetamine and, despite showing some desirable qualities such as reduced toxicity as compared to amphetamine, was chosen to not be developed as a medicinal drug.<ref>MDPV Summary | http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref> | MDPV was first developed in the 1960s by a team at Boehringer Ingelheim.<ref name="KoppePatent">{{Citation | vauthors=((Koppe, H.)), ((Ludwig, G.)), ((Zeile, K.)) | title=1-(3’,4’-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1) | url=https://patents.google.com/patent/US3478050/en}}</ref> It was claimed to have potential to be an alternative for racemic amphetamine and, despite showing some desirable qualities such as reduced toxicity as compared to amphetamine, was chosen to not be developed as a medicinal drug.<ref>MDPV Summary | http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref> | ||